The authors reply [11]

New England Journal of Medicine

Volumn 356, Issue 12, 2007, Pages 1271-

  Hoofnagle, Jay H ^a   Seeff, Leonard B ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ERYTHROPOIETIN; PEGINTERFERON;

ALCOHOL CONSUMPTION; AUTOIMMUNE DISEASE; CLINICAL FEATURE; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LETTER; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; RISK BENEFIT ANALYSIS; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 33947529748     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71. [Erratum, Hepatology 2004;40:269.]
2. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-64.
3. Conjeevaram HS, Kleiner DE, Everhart JE, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007;45:80-7.
4. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-81.
5. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-Year follow-up after interferon-? therapy for chronic hepatitis C. Hepatology 1998;28:1121-7.